Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function

Pa, Soons; Ankermann, Tobias; Dd, Breimer; Kirch, Wilhelm

doi:10.1007/bf00280129

Cited by 5 publications

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Dosing of Antihypertensive Medications in Patients with Renal Insufficiency

Carter

1995

The Journal of Clinical Pharma

View full text Add to dashboard Cite

The use of antihypertensive agents in patients with renal insufficiency necessitates careful consideration of dosages, titration, and monitoring. Renal function must be estimated to appropriately make dosage adjustments for antihypertensives that exhibit extensive renal elimination. Thiazide diuretics are useful in mild degrees of renal insufficiency but loop diuretics become necessary as renal function deteriorates further. With either class, low dosages should be used to prevent hypovolemia, hyponatremia, and hypokalemia which may worsen renal blood flow. Angiotensin-converting enzyme (ACE) inhibitors have become popular because they may have unique renal protective properties. All ACE inhibitors except fosinopril require reduced dosages and/or less frequent administration in patients with renal insufficiency. It is often necessary to use a diuretic with an ACE inhibitor and special dosing considerations are important. Due to demographic and physiologic characteristics of patients with renal insufficiency, beta blockers are often reserved for patients with other indications for beta blockers such as ischemic heart disease. Several beta blockers are eliminated primarily by the kidney and dosage reductions are necessary for these agents. Calcium antagonists may also have renal protective effects. Because calcium antagonists are metabolized extensively, significant dosage adjustments are not necessary. Data suggest that antihypertensives may slow the decline in renal insufficiency. The pharmacokinetics of several antihypertensives change with renal impairment because of reduced elimination. Therefore, dosage adjustments, slower titration, and less frequent administration are often necessary.

show abstract

Dosing of Antihypertensive Medications in Patients with Renal Insufficiency

Carter

1995

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

Bunazosin in patients with impaired hepatic or renal function

Halabi

Nokhodian

Kirch

1993

Eur. J. Drug Metab. Pharmacokinet.

Self Cite

View full text Add to dashboard Cite

Following a single oral dose of 6 mg bunazosin, a novel alpha 1-adrenoceptor antagonist, the pharmacokinetics and blood pressure behaviour of 37 patients were studied. 12 subjects had normal renal and hepatic function (mean creatinine clearance (GFR) 107 +/- 240 ml/min, antipyrine clearance (AP Cl) 47 +/- 10.2 ml/min; x +/- SD), 13 subjects had impaired renal function (mean GFR 38 +/- 11.5 ml/min, AP Cl 39 +/- 4.0 ml/min), and 12 patients had liver cirrhosis which was confirmed by liver biopsy (mean AP Cl 18 +/- 9.2 ml/min, GFR 92 +/- 8.1 ml/min). The groups studied were matched for age and body weight. The area under the plasma level time curve (AUC0-infinity) of bunazosin increased from 96.6 +/- 48.7 micrograms.ml-1.h in the normals to 157.0 +/- 101.0 micrograms.ml-1.h in the liver patients and to 298.2 +/- 199.4 micrograms.ml-1.h in patients with impaired renal function (P < 0.05). As there was a close correlation between plasma levels and antihypertensive activity of bunazosin in the present study, dosage adjustment of the alpha 1-receptor blocker in patients with impaired liver and kidney function appears to be mandatory.

show abstract

Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function

Kirch

Nokhodian

Halabi

et al. 1992

European Journal of Drug Metabolism and Pharmacokinetics

Self Cite

View full text Add to dashboard Cite

Following a single oral dose of 20 mg nifedipine combined with 2 mg co-dergocrine to 24 subjects, the pharmacokinetics of this drug were studied. 8 normotensive subjects had normal renal and hepatic function, 8 patients had chronic renal insufficiency (creatinine clearance less than 30 ml.min-1) and 8 patients had liver cirrhosis which was confirmed by liver biopsy. The area under the plasma level time curve (AUC infinity) of co-dergocrine increased from 0.59 +/- 0.41 ng.ml-1. (mean +/- SD) in the normals to 1.24 +/- 0.95 ng.ml-1.h in liver cirrhosis (P less than 0.05) and to 1.81 +/- 0.9 ng.ml-1.h in renal failure (P less than 0.05 compared with the control group). Corresponding values for the nifedipine AUC infinity were 564.5 +/- 268 ng.ml-1.h, 1547.5 +/- 1134 (P less than 0.05) and 929 +/- 533 ng.ml-1.h (P less than 0.05; gas chromatographic method). The incidence of adverse effects was lower in patients with renal failure than in subjects with normal renal and liver function as well as in those with liver cirrhosis.

show abstract

Stereoselective pharmacokinetics of oral nitrendipine in elderly hypertensive patients with normal and impaired renal function

Cited by 5 publications

References 26 publications

Dosing of Antihypertensive Medications in Patients with Renal Insufficiency

Dosing of Antihypertensive Medications in Patients with Renal Insufficiency

Bunazosin in patients with impaired hepatic or renal function

Clinical pharmacokinetics of the nifedipine/co-dergocrine combination in impaired liver and renal function

Contact Info

Product

Resources

About